Zacks.com Featured Highlights Include ADMA Biologics, American Superconductor, Biote, Lincoln Educational Services and Corcept Therapeutics
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
Most readers would already be aware that Corcept Therapeutics' (NASDAQ:CORT) stock increased significantly by 35% over the past three months. Given that the market rewards strong financials in the
Truist Financial Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
High Insider Ownership Growth Companies On US Exchanges In July 2024
Corcept Therapeutics(CORT.US) Officer Sells US$162.45K in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas sold 5,000 shares of common stock on Jul 1, 2024 at an average price of $32.4904 for a total value of $162.45K.Source: Announcement What is
Corcept Therapeutics(CORT.US) Officer Sells US$324.9K in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Guyer William sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $32.49 for a total value of $324.9K.Source: Announcement What is statemen
Corcept Therapeutics(CORT.US) Officer Sells US$357.39K in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Robb Gary Charles sold 11,000 shares of common stock on Jul 1, 2024 at an average price of $32.49 for a total value of $357.39K.Source: Announcement What is sta
Corcept Therapeutics(CORT.US) Director Sells US$72,182 in Common Stock
$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of common stock on Jul 1, 2024 at an average price of $32.81 for a total value of $72,182.Source: Announcement What is st
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 357.39K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Robb Gary Charles intends to sell 11,000 shares of its common stock on Jul 1, with a total market value of approximately $357.39K
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 162.45K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on Jul 1, with a total market value of approximately $162.45
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 324.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Guyer William intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $324.9K. G
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $35
Piper Sandler analyst David Amsellem maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41
Corcept Therapeutics (CORT) Receives a Buy From Piper Sandler
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficu
Express News | Corcept Therapeutics Inc - Results Demonstrate a Hypercortisolism Prevalence Rate of 24 Percent in This Patient Population
Express News | Corcept Announces Presentation of Results From Prevalence Phase of Catalyst Clinical Trial at American Diabetes Association’s Scientific Sessions
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
6 Analysts Have This To Say About Corcept Therapeutics
During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish.The table below provides a snapshot of their
Corcept Therapeutics Is Maintained at Buy by Truist Securities
Corcept Therapeutics Is Maintained at Buy by Truist Securities